Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Apr 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of kidney biopsies in patients with solid tumors who are being treated with a type of immunotherapy called checkpoint inhibitors. These treatments can sometimes cause kidney damage, known as nephrotoxicity, which can lead to acute kidney failure. The researchers aim to create a score that helps doctors determine if kidney damage is occurring and to decide the best course of action for treatment, including whether to continue or pause the immunotherapy. This is important because kidney biopsies can carry risks, and the goal is to avoid unnecessary procedures while ensuring patients receive the right care.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with a solid cancer that is being treated with immunotherapy, with or without chemotherapy. If you are experiencing kidney failure and have had a kidney biopsy, you may be eligible. Participants in the study will help researchers understand how to better manage kidney issues related to immunotherapy, potentially improving care for future patients facing similar challenges. There are no specific exclusion criteria, so many patients may find they can join the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient over 18 years old Diagnosis of solid cancer treated by immunotherapy such as checkpoint inhibitor, associated or not with chemotherapy Renal failure having benefited from a renal biopsy
• Exclusion Criteria:
• • None